Komori
Statutory disclosure document4583Chiome Bioscience Inc.Pharmaceuticals

Notice of U.S. Patent Allowance for Combination of a Humanized DLK-1 Antibody and an FGFR4 Inhibitor

The company received a notice of allowance for a U.S. patent application covering the combination of a humanized DLK-1 antibody and an FGFR4 inhibitor. This advances the acquisition of U.S. intellectual property rights for combinations of antibodies, including CBA-1205, and FGFR4 inhibitors.

Worth reading
53Recurring
Scored from 4 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Decision and Details

U.S. Patent Allowance for Combination of a Humanized DLK-1 Antibody and an FGFR4 Inhibitor

Decision16 November 2026 (date the notice of allowance was received)
Going forwardPatent applications are also pending in Europe, China and other jurisdictions. For CBA-1205, we aim to out-license the product to a pharmaceutical company using safety and preliminary efficacy data obtained from the domestic Phase 1 clinical trial.
Quantity / scaleU.S. patent application No.18/030,203
Reason

Because we believe this will strengthen the intellectual property foundation supporting our development and out-licensing activities.

Impact on Business Performance

This matter will have no impact on results for the fiscal year ending December 2026.

Title of inventionPharmaceutical for cancer treatment
Patent holderChiome Bioscience Inc.
Decision and Details
ItemDetails
Matter CoveredU.S. Patent Allowance for Combination of a Humanized DLK-1 Antibody and an FGFR4 Inhibitor
Decision Date16 November 2026 (date the notice of allowance was received)
Quantity / scaleU.S. patent application No.18/030,203
Impact on Business PerformanceThis matter will have no impact on results for the fiscal year ending December 2026.
ReasonBecause we believe this will strengthen the intellectual property foundation supporting our development and out-licensing activities.
Future plansPatent applications are also pending in Europe, China and other jurisdictions. For CBA-1205, we aim to out-license the product to a pharmaceutical company using safety and preliminary efficacy data obtained from the domestic Phase 1 clinical trial.
Title of inventionPharmaceutical for cancer treatment
Patent holderChiome Bioscience Inc.
Items this document does not state (6)
Decision-Making BodyImplementation DatePeriod CoveredAmountGoverning RuleRelated previous disclosures

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen the intellectual property foundation supporting our development and out-licensing activities.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of U.S. Patent Allowance for Combination of a Humanized DLK-1 Antibody and an FGFR4 Inhibitor | Chiome Bioscience Inc. (4583) timely disclosure | Komori